
We aimed to examine the association between changes in lipids and markers of haemoconcentration (haematocrit and serum albumin) with empagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in patients with type 2 diabetes (T2D) using pooled data from four phase 3 randomized trials. Haematocrit and serum albumin increases were associated with increases in lipid fractions with empagliflozin. Empagliflozin‐associated changes in serum lipids, particularly LDL‐cholesterol increases, may be partly attributable to haemoconcentration resulting from increased urinary volume and subsequent volume contraction.
Like
Save
Share